Neurocrine Biosciences | NBIX - Assets


Neurocrine Biosciences reported $4.91B in Assets for its fiscal quarter ending in March of 2026.





Assets Change Date
AbbVie USD 136.46B 2.5B Mar/2026
Acadia Pharmaceuticals USD 1.61B 41.04M Mar/2026
Agios Pharmaceuticals USD 1.18B 112.24M Mar/2026
ALKERMES USD 4.26B 1.77B Mar/2026
Alnylam Pharmaceuticals USD 5.13B 163.22M Mar/2026
Amgen USD 92.5B 1.92B Mar/2026
Biogen USD 29.48B 43.6M Mar/2026
BioMarin Pharmaceutical USD 8.59B 996.99M Mar/2026
Cytokinetics USD 1.27B 151.06M Mar/2026
Enanta Pharmaceuticals USD 329.5M 48.77M Dec/2025
Exelixis USD 2.59B 250.83M Mar/2026
Gilead Sciences USD 56.28B 2.74B Mar/2026
Halozyme Therapeutics USD 2.67B 147.4M Mar/2026
Incyte USD 7.34B 381.14M Mar/2026
Ionis Pharmaceuticals USD 3.45B 74M Mar/2026
Nektar Therapeutics USD 280.41M 20.94M Dec/2025
Neurocrine Biosciences USD 4.91B 274.7M Mar/2026
Pfizer USD 207.62B 542M Mar/2026
Prothena USD 349.89M 23.09M Mar/2026
Regeneron Pharmaceuticals USD 40.87B 310.1M Mar/2026
Repligen USD 2.93B 18.93M Mar/2026
Rigel Pharmaceuticals USD 242.53M 35.8M Sep/2025
Sarepta Therapeutics USD 3.18B 170.77M Mar/2026
Teva Pharmaceutical Industries USD 40.04B 708M Mar/2026
Ultragenyx Pharmaceutical USD 1.3B 236M Mar/2026
Vertex Pharmaceuticals USD 26.48B 841.4M Mar/2026
Xoma USD 263.15M 39.7M Sep/2025